TABLE 4.
Comparison of 90Y (resin and glass-based) and 166Ho microspheres for radioembolization
| SIR-Spheres™ | Therasphere™ | QuiremSpheres™ | |
|---|---|---|---|
| Matrix | Resin | Glass | PLLA |
| Diameter | 20-60μm (mean 32 μm) | 25 μm | 30 μm |
| Isotope | Yttrium-90 | Holmium-166 | |
| T 1/2 | 64.5 hours | 26.8 hours | |
| Density | 1.6 g/cm3 | 3.4 g/cm3 | 1.4 g/cm3 |
| Number of spheres | 33-50 mln | 4 mln | 33 mln |
| Amount per dose | 900-1370 mg | 110 mg | 600 mg |
| Activity per sphere | 50 Bq | 1250-2500 Bq | 200-400 Bq |
| Activity per dose | 2-3 GBq | 5-15 GBq | 6-12 GBq |
| Imaging | Y-90 PET or Bremsstrahlung SPECT/CT | SPECT/MRI/CT | |
| Test dose | 99m Tc-MAA | Ho-spheres/Tc-MAA | |
| Company | Sirtex Medical Limited, NSW, Australia | BTG, London, UK | Terumo, Nijmegen, NL |
| Year of creation | 1974 | 1989 | 1994 |
| CE trade mark | 2002 | 1999 | 2014 |
| FDA indications | Unresectable colorectal liver metastases in combination with intrahepatic floxuridine | Humanitarian device exemption for unresectable HCC | Unresectable colorectal liver metastases |
| Activity calculation | BSA, partition model | MIRD-based approach | Two-compartment-based dosimetry |